Really appreciate how clearly you laid out the FDA's case here — the 455+ adverse event reports tied to compounded semaglutide is a stat that deserved far more mainstream visibility. The tension between safety and access is real, especially for patients who relied on compounded versions while brand-name supply was limited. With the June 29 comment window open, this is a critical moment for patients and clinicians to weigh in. Thank you for this!
Really appreciate how clearly you laid out the FDA's case here — the 455+ adverse event reports tied to compounded semaglutide is a stat that deserved far more mainstream visibility. The tension between safety and access is real, especially for patients who relied on compounded versions while brand-name supply was limited. With the June 29 comment window open, this is a critical moment for patients and clinicians to weigh in. Thank you for this!
Thank you so much for this insight and your kind words. 🙏 You could not be more correct.